492 articles for thisTarget
The following articles (labelled with PubMed ID or TBD) are for your review
PMID
Cmpds
Data
Article Title
Organization
19
New pyridazinone-4-carboxamides as new cannabinoid receptor type-2 inverse agonists: Synthesis, pharmacological data and molecular docking.
University of Sassari
49
Structure-anticonvulsant activity studies in the group of (E)-N-cinnamoyl aminoalkanols derivatives monosubstituted in phenyl ring with 4-Cl, 4-CH
Jagiellonian University Medical College
36
Synthesis, binding assays, cytotoxic activity and docking studies of benzimidazole and benzothiophene derivatives with selective affinity for the CB2 cannabinoid receptor.
Pontificia Universidad Cat£Lica De Chile
33
Discovery of novel Tetrahydrobenzo[b]thiophene and pyrrole based scaffolds as potent and selective CB2 receptor ligands: The structural elements controlling binding affinity, selectivity and functionality.
German University In Cairo
23
Tetrahydropyrazolo[4,3-c]pyridine derivatives as potent and peripherally selective cannabinoid-1 (CB1) receptor inverse agonists.
Janssen Research and Development
23
Tetrahydroindazole derivatives as potent and peripherally selective cannabinoid-1 (CB1) receptor inverse agonists.
Janssen Research and Development
15
A critical review of both the synthesis approach and the receptor profile of the 8-chloro-1-(2',4'-dichlorophenyl)-N-piperidin-1-yl-1,4,5,6-tetrahydrobenzo[6,7]cyclohepta[1,2-c]pyrazole-3-carboxamide and analogue derivatives.
Neuroscienze Pharmaness S.C.A R.L.
4
Discovery of KLS-13019, a Cannabidiol-Derived Neuroprotective Agent, with Improved Potency, Safety, and Permeability.
Kannalife Sciences
27
Synthesis and pharmacological evaluation of new biphenylic derivatives as CB2 receptor ligands.
University of Pisa
15
Development and Pharmacological Characterization of Selective Blockers of 2-Arachidonoyl Glycerol Degradation with Efficacy in Rodent Models of Multiple Sclerosis and Pain.
University of Siena
19
Identification of Novel GPR55 Modulators Using Cell-Impedance-Based Label-Free Technology.
Instituto De Qu£Mica M£Dica
25
Investigations on the 4-Quinolone-3-carboxylic Acid Motif. 7. Synthesis and Pharmacological Evaluation of 4-Quinolone-3-carboxamides and 4-Hydroxy-2-quinolone-3-carboxamides as High Affinity Cannabinoid Receptor 2 (CB2R) Ligands with Improved Aqueous Solubility.
University of Siena
47
Design, physico-chemical properties and biological evaluation of some new N-[(phenoxy)alkyl]- and N-{2-[2-(phenoxy)ethoxy]ethyl}aminoalkanols as anticonvulsant agents.
Jagiellonian University Medical College
20
Tricyclic pyrazoles. Part 8. Synthesis, biological evaluation and modelling of tricyclic pyrazole carboxamides as potential CB2 receptor ligands with antagonist/inverse agonist properties.
University of Sassari
30
Synthesis and structure activity relationship investigation of triazolo[1,5-a]pyrimidines as CB2 cannabinoid receptor inverse agonists.
University of Ferrara
12
Pyrazole antagonists of the CB1 receptor with reduced brain penetration.
Rti International
24
Synthesis, pharmacological evaluation and docking studies of pyrrole structure-based CB2 receptor antagonists.
University of Sassari
24
Synthesis and biological evaluation of (3',5'-dichloro-2,6-dihydroxy-biphenyl-4-yl)-aryl/alkyl-methanone selective CB2 inverse agonist.
University of Tennessee Health Science Center
4
Combining Mass Spectrometric Metabolic Profiling with Genomic Analysis: A Powerful Approach for Discovering Natural Products from Cyanobacteria.
University of California Berkeley
11
Distinct Temporal Fingerprint for Cyclic Adenosine Monophosphate (cAMP) Signaling of Indole-2-carboxamides as Allosteric Modulators of the Cannabinoid Receptors.
University of Auckland
62
Development of Quinoline-2,4(1H,3H)-diones as Potent and Selective Ligands of the Cannabinoid Type 2 Receptor.
Zhejiang University
10
Isolation and Pharmacological Evaluation of Minor Cannabinoids from High-Potency Cannabis sativa.
The University of Mississippi
11
Novel azoles as potent and selective cannabinoid CB2 receptor agonists.
Ipsen Innovation
6
Cannabinoid type 1 receptor antagonists modulate transport activity of multidrug resistance-associated proteins MRP1, MRP2, MRP3, and MRP4.
Radboud University Nijmegen Medical Centre
12
New quinolone- and 1,8-naphthyridine-3-carboxamides as selective CB2 receptor agonists with anticancer and immuno-modulatory activity.
University of Pisa
24
Conformational Restriction Leading to a Selective CB2 Cannabinoid Receptor Agonist Orally Active Against Colitis.
University of Lille
3
Selective, nontoxic CB(2) cannabinoid o-quinone with in vivo activity against triple-negative breast cancer.
Instituto De Qu£Mica M£Dica
95
Design, syntheses, structure-activity relationships and docking studies of coumarin derivatives as novel selective ligands for the CB2 receptor.
Zhejiang University
10
Synthesis, radiolabeling and evaluation of novel 4-oxo-quinoline derivatives as PET tracers for imaging cannabinoid type 2 receptor.
Institute of Pharmaceutical Sciences
34
Structure-activity relationships of substituted 1H-indole-2-carboxamides as CB1 receptor allosteric modulators.
Research Triangle Institute
19
Selective CB2 receptor agonists. Part 1: the identification of novel ligands through computer-aided drug design (CADD) approaches.
Boehringer Ingelheim Pharmaceuticals
14
Synthesis, biological activity and molecular modeling of new biphenylic carboxamides as potent and selective CB2 receptor ligands.
University of Pisa
30
Design, synthesis and in vitro evaluation of novel uni- and bivalent ligands for the cannabinoid receptor type 1 with variation of spacer length and structure.
Julius-Maximilians-Universit£T W£Rzburg
15
One-pot heterogeneous synthesis of¿(3)-tetrahydrocannabinol analogues and xanthenes showing differential binding to CB(1) and CB(2) receptors.
University of Perugia
35
Structure-affinity relationships and pharmacological characterization of new alkyl-resorcinol cannabinoid receptor ligands: Identification of a dual cannabinoid receptor/TRPA1 channel agonist.
University of Siena
15
Synthesis and biological evaluation of bivalent cannabinoid receptor ligands based on hCB2R selective benzimidazoles reveal unexpected intrinsic properties.
Julius-Maximilians-Universit£T W£Rzburg
8
Identification of endocannabinoid system-modulating N-alkylamides from Heliopsis helianthoides var. scabra and Lepidium meyenii.
University of Szeged
1
DDD-028: a potent potential non-opioid, non-cannabinoid analgesic for neuropathic and inflammatory pain.
University of Missouri
40
Selective CB2 receptor agonists. Part 3: the optimization of a piperidine-based series that demonstrated efficacy in an in vivo neuropathic pain model.
Boehringer Ingelheim Pharmaceuticals
34
Selective CB2 receptor agonists. Part 2: Structure-activity relationship studies and optimization of proline-based compounds.
Boehringer Ingelheim Pharma
31
Identification of a highly potent and selective CB2 agonist, RQ-00202730, for the treatment of irritable bowel syndrome.
Raqualia Pharma
43
Discovery of 1a,2,5,5a-tetrahydro-1H-2,3-diaza-cyclopropa[a]pentalen-4-carboxamides as potent and selective CB2 receptor agonists.
Arena Pharmaceuticals
58
Ligand-based virtual screening identifies a family of selective cannabinoid receptor 2 agonists.
University of Oxford
11
The SAR development of substituted purine derivatives as selective CB2 agonists for the treatment of chronic pain.
Eli Lilly
36
CB2-selective cannabinoid receptor ligands: synthesis, pharmacological evaluation, and molecular modeling investigation of 1,8-Naphthyridin-2(1H)-one-3-carboxamides.
University of Pisa
27
The design and implementation of a generic lipopeptide scanning platform to enable the identification of 'locally acting' agonists for the apelin receptor.
Novartis Institutes For Biomedical Research
37
Diarylureas as allosteric modulators of the cannabinoid CB1 receptor: structure-activity relationship studies on 1-(4-chlorophenyl)-3-{3-[6-(pyrrolidin-1-yl)pyridin-2-yl]phenyl}urea (PSNCBAM-1).
Research Triangle Institute
12
Tricyclic pyrazoles. Part 6. Benzofuro[3,2-c]pyrazole: a versatile architecture for CB2 selective ligands.
University of Sassari
46
Development of novel benzomorpholine class of diacylglycerol acyltransferase I inhibitors.
Merck Research Laboratories
3
Ultrapure ajulemic acid has improved CB2 selectivity with reduced CB1 activity.
Corbus Pharmaceuticals
1
The cannabinoid acids, analogs and endogenous counterparts.
The University of Massachusetts Medical School
26
Reductions in log P improved protein binding and clearance predictions enabling the prospective design of cannabinoid receptor (CB1) antagonists with desired pharmacokinetic properties.
Bristol Myers Squibb
88
Therapeutic utility of cannabinoid receptor type 2 (CB(2)) selective agonists.
Arena Pharmaceuticals
13
Evaluation of (Z)-2-((1-benzyl-1H-indol-3-yl)methylene)-quinuclidin-3-one analogues as novel, high affinity ligands for CB1 and CB2 cannabinoid receptors.
University of Arkansas For Medical Sciences
14
Novel antiobesity agents: synthesis and pharmacological evaluation of analogues of Rimonabant and of LH21.
Instituto De Qu£Mica M£Dica
24
Highly potent and selective cannabinoid receptor 2 agonists: initial hit optimization of an adamantyl hit series identified from high-through-put screening.
F. Hoffmann-La Roche
51
Trisubstituted Sulfonamides: a New Chemotype for Development of Potent and Selective CB
University of Pittsburgh
8
Magnolia Extract, Magnolol, and Metabolites: Activation of Cannabinoid CB2 Receptors and Blockade of the Related GPR55.
University of Bonn
51
Novel triaryl sulfonamide derivatives as selective cannabinoid receptor 2 inverse agonists and osteoclast inhibitors: discovery, optimization, and biological evaluation.
University of Pittsburgh
42
Design, synthesis, and pharmacological properties of new heteroarylpyridine/heteroarylpyrimidine derivatives as CB(2) cannabinoid receptor partial agonists.
University of Ferrara
38
Discovery of agonists of cannabinoid receptor 1 with restricted central nervous system penetration aimed for treatment of gastroesophageal reflux disease.
AstraZeneca
23
Arylsulfonamides as a new class of cannabinoid CB1 receptor ligands: identification of a lead and initial SAR studies.
Ucb Pharma
30
Design, synthesis, and pharmacological characterization of indol-3-ylacetamides, indol-3-yloxoacetamides, and indol-3-ylcarboxamides: potent and selective CB2 cannabinoid receptor inverse agonists.
University of Siena
28
Pharmacokinetic optimisation of novel indole-2-carboxamide cannabinoid CB1 antagonists.
Msd
22
Discovery of potent and orally bioavailable heterocycle-based cannabinoid CB1 receptor agonists.
Merck Research Laboratories
19
Design, synthesis, and structure-activity relationship study of conformationally constrained analogs of indole-3-carboxamides as novel CB1 cannabinoid receptor agonists.
Schering-Plough Research Institute
36
Synthesis and evaluation of 3-amino-6-aryl-pyridazines as selective CB(2) agonists for the treatment of inflammatory pain.
Glaxosmithkline
34
2-Amino-5-aryl-pyridines as selective CB2 agonists: synthesis and investigation of structure-activity relationships.
Glaxosmithkline
35
Predictive models of Cannabinoid-1 receptor antagonists derived from diverse classes.
Korea Research Institute of Chemical Technology
65
Structure-activity relationships of 2-arylamido-5,7-dihydro-4H-thieno[2,3-c]pyran-3-carboxamide derivatives as cannabinoid receptor agonists and their analgesic action.
Nycomed Pharma
30
Synthesis and pharmacology of 1-alkyl-3-(1-naphthoyl)indoles: steric and electronic effects of 4- and 8-halogenated naphthoyl substituents.
Rti International
18
Diphenyl purine derivatives as peripherally selective cannabinoid receptor 1 antagonists.
Research Triangle Institute
55
Lead discovery, chemistry optimization, and biological evaluation studies of novel biamide derivatives as CB2 receptor inverse agonists and osteoclast inhibitors.
University of Pittsburgh
33
7-Alkyl-3-benzylcoumarins: a versatile scaffold for the development of potent and selective cannabinoid receptor agonists and antagonists.
University of Bonn
30
4-Oxo-1,4-dihydropyridines as selective CB2 cannabinoid receptor ligands. Part 2: discovery of new agonists endowed with protective effect against experimental colitis.
University of Lille
47
7-Oxo-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxamides as selective CB(2) cannabinoid receptor ligands: structural investigations around a novel class of full agonists.
University of Ferrara
25
2-Arylbenzofuran-based molecules as multipotent Alzheimer's disease modifying agents.
University of Bologna
16
Scaffold hopping strategy toward original pyrazolines as selective CB2 receptor ligands.
Rue de l'Universite
40
Investigations on the 4-quinolone-3-carboxylic acid motif. 6. Synthesis and pharmacological evaluation of 7-substituted quinolone-3-carboxamide derivatives as high affinity ligands for cannabinoid receptors.
University of Siena
43
JD-5006 and JD-5037: peripherally restricted (PR) cannabinoid-1 receptor blockers related to SLV-319 (Ibipinabant) as metabolic disorder therapeutics devoid of CNS liabilities.
Jenrin Discovery
31
Structure and activity relationship in the (S)-N-chroman-3-ylcarboxamide series of voltage-gated sodium channel blockers.
AstraZeneca
23
Indole-2-carboxamides as allosteric modulators of the cannabinoid CB1 receptor.
Sapienza University of Rome
22
Design of a Potent CB1 Receptor Antagonist Series: Potential Scaffold for Peripherally-Targeted Agents.
TBA
12
Discovery and optimization of novel purines as potent and selective CB2 agonists.
Eli Lilly
25
N-Methyl-3-(tetrahydro-2H-pyran-4-yl)-2,3,4,9-tetrahydro-1H-carbazole-6-carboxamides as a novel class of cannabinoid receptors agonists with low CNS penetration.
AstraZeneca
35
Design and synthesis of cannabinoid receptor 1 antagonists for peripheral selectivity.
Research Triangle Institute
18
Discovery of S-444823, a potent CB1/CB2 dual agonist as an antipruritic agent.
Shionogi
1
Identification of a Potent and Selective Cannabinoid CB1 Receptor Antagonist from Auxarthron reticulatum.
TBA
19
Rational design, synthesis and anti-proliferative properties of new CB2 selective cannabinoid receptor ligands: an investigation of the 1,8-naphthyridin-2(1H)-one scaffold.
University of Pisa
17
Discovery of S-777469: an orally available CB2 agonist as an antipruritic agent.
Shionogi
17
CB 1/2 dual agonists with 3-carbamoyl 2-pyridone derivatives as antipruritics: reduction of CNS side effects by introducing polar functional groups.
Shionogi
4
Low brain penetrant CB1 receptor agonists for the treatment of neuropathic pain.
Merck Research Laboratories
13
Synthesis and evaluation of 2-amido-3-carboxamide thiophene CB2 receptor agonists for pain management.
Abbott Laboratories
22
N-(4-cyanotetrahydro-2H-pyran-4-yl) and N-(1-cyanocyclohexyl) derivatives of 1,5-diarylpyrazole-3-carboxamides showing high affinity for 18 kDa translocator protein and/or cannabinoid receptors.
National Institute of Mental Health
39
Discovery of {1-[4-(2-{hexahydropyrrolo[3,4-c]pyrrol-2(1H)-yl}-1H-benzimidazol-1-yl)piperidin-1-yl]cyclooctyl}methanol, systemically potent novel non-peptide agonist of nociceptin/orphanin FQ receptor as analgesic for the treatment of neuropathic pain: design, synthesis, and structure-activity rela
Pfizer
10
1-Bromo-3-(1',1'-dimethylalkyl)-1-deoxy-¿(8)-tetrahydrocannabinols: New selective ligands for the cannabinoid CB(2) receptor.
Clemson University
34
Discovery of N-{1-[3-(3-oxo-2,3-dihydrobenzo[1,4]oxazin-4-yl)propyl]piperidin-4-yl}-2-phenylacetamide (Lu AE51090): an allosteric muscarinic M1 receptor agonist with unprecedented selectivity and procognitive potential.
H. Lundbeck
37
Investigations on the 4-quinolone-3-carboxylic acid motif. 3. Synthesis, structure-affinity relationships, and pharmacological characterization of 6-substituted 4-quinolone-3-carboxamides as highly selective cannabinoid-2 receptor ligands.
University of Siena
16
Probing the cannabinoid CB1/CB2 receptor subtype selectivity limits of 1,2-diarylimidazole-4-carboxamides by fine-tuning their 5-substitution pattern.
Solvay Pharma
21
Synthesis, SAR and intramolecular hydrogen bonding pattern of 1,3,5-trisubstituted 4,5-dihydropyrazoles as potent cannabinoid CB(1) receptor antagonists.
Solvay Pharma
18
Synthesis and SAR of novel imidazoles as potent and selective cannabinoid CB2 receptor antagonists with high binding efficiencies.
Solvay Pharma
57
Synthesis, cannabinoid receptor affinity, molecular modeling studies and in vivo pharmacological evaluation of new substituted 1-aryl-5-(1H-pyrrol-1-yl)-1H-pyrazole-3-carboxamides. 2. Effect of the 3-carboxamide substituent on the affinity and selectivity profile.
Sapienza University of Rome
33
Discovery and functional evaluation of diverse novel human CB(1) receptor ligands.
Vernalis (R&D)
17
Rational design, synthesis, and pharmacological properties of new 1,8-naphthyridin-2(1H)-on-3-carboxamide derivatives as highly selective cannabinoid-2 receptor agonists.
Universita Di Pisa
36
Synthesis and pharmacological evaluation of coumarin derivatives as cannabinoid receptor antagonists and inverse agonists.
University of Bonn
27
Discovery of novel CB2 receptor ligands by a pharmacophore-based virtual screening workflow.
University of Innsbruck
19
6-Methoxy-N-alkyl isatin acylhydrazone derivatives as a novel series of potent selective cannabinoid receptor 2 inverse agonists: design, synthesis, and binding mode prediction.
The University of Texas M.D. Anderson Cancer Center
44
Discovery and optimization of a novel series of N-arylamide oxadiazoles as potent, highly selective and orally bioavailable cannabinoid receptor 2 (CB2) agonists.
Amgen
23
Investigations on the 4-quinolone-3-carboxylic acid motif. 2. Synthesis and structure-activity relationship of potent and selective cannabinoid-2 receptor agonists endowed with analgesic activity in vivo.
University of Siena
18
Design and synthesis of a novel series of N-alkyl isatin acylhydrazone derivatives that act as selective cannabinoid receptor 2 agonists for the treatment of neuropathic pain.
The University of Texas M.D. Anderson Cancer Center
17
Alkaloids from Eschscholzia californica and their capacity to inhibit binding of [3H]8-Hydroxy-2-(di-N-propylamino)tetralin to 5-HT1A receptors in Vitro.
Tom'S of Maine
19
New tetrazole-based selective anandamide uptake inhibitors.
Sapienza University of Rome
19
Imine derivatives as new potent and selective CB2 cannabinoid receptor agonists with an analgesic action.
Taisho Pharmaceutical
2
Conformational analysis and receptor docking of N-[(1S,2S)-3-(4-chlorophenyl)-2-(3-cyanophenyl)-1-methylpropyl]-2-methyl-2-{[5-(trifluoromethyl)pyridin-2-yl]oxy}propanamide (taranabant, MK-0364), a novel, acyclic cannabinoid-1 receptor inverse agonist.
Merck Research Laboratories
2
A-803467, a potent and selective Nav1.8 sodium channel blocker, attenuates neuropathic and inflammatory pain in the rat.
Abbott Laboratories
17
New 1,8-naphthyridine and quinoline derivatives as CB2 selective agonists.
University of Pisa
26
N-Alkylidenearylcarboxamides as new potent and selective CB(2) cannabinoid receptor agonists with good oral bioavailability.
Taisho Pharmaceutical
9
Naphthalen-1-yl-(4-pentyloxynaphthalen-1-yl)methanone: a potent, orally bioavailable human CB1/CB2 dual agonist with antihyperalgesic properties and restricted central nervous system penetration.
Novartis Institutes For Biomedical Research
25
Design, synthesis, binding, and molecular modeling studies of new potent ligands of cannabinoid receptors.
University of Siena
16
1-Benzhydryl-3-phenylurea and 1-benzhydryl-3-phenylthiourea derivatives: new templates among the CB1 cannabinoid receptor inverse agonists.
University of Louvain
29
Design, synthesis, and binding studies of new potent ligands of cannabinoid receptors.
University of Siena
13
Discovery of N-[(1S,2S)-3-(4-Chlorophenyl)-2- (3-cyanophenyl)-1-methylpropyl]-2-methyl-2- {[5-(trifluoromethyl)pyridin-2-yl]oxy}propanamide (MK-0364), a novel, acyclic cannabinoid-1 receptor inverse agonist for the treatment of obesity.
Merck Research Laboratories
21
Synthesis and activity of 1,3,5-triphenylimidazolidine-2,4-diones and 1,3,5-triphenyl-2-thioxoimidazolidin-4-ones: characterization of new CB1 cannabinoid receptor inverse agonists/antagonists.
University of Louvain
29
Novel 4-oxo-1,4-dihydroquinoline-3-carboxamide derivatives as new CB2 cannabinoid receptors agonists: synthesis, pharmacological properties and molecular modeling.
University of Lille
39
New metabolically stable fatty acid amide ligands of cannabinoid receptors: Synthesis and receptor affinity studies.
Institute of Biomolecular Chemistry
17
Novel 3,4-diarylpyrazolines as potent cannabinoid CB1 receptor antagonists with lower lipophilicity.
Solvay Pharma
33
Bioisosteric replacements of the pyrazole moiety of rimonabant: synthesis, biological properties, and molecular modeling investigations of thiazoles, triazoles, and imidazoles as potent and selective CB1 cannabinoid receptor antagonists.
Solvay Pharma
41
The endocannabinoid system: drug targets, lead compounds, and potential therapeutic applications.
University of Louvain
10
Rational design and synthesis of an orally active indolopyridone as a novel conformationally constrained cannabinoid ligand possessing antiinflammatory properties.
Bristol Myers Squibb
6
Exploration of the pharmacophore of 3-alkyl-5-arylimidazolidinediones as new CB(1) cannabinoid receptor ligands and potential antagonists: synthesis, lipophilicity, affinity, and molecular modeling.
University of Lausanne
5
The bioactive conformation of aminoalkylindoles at the cannabinoid CB1 and CB2 receptors: insights gained from (E)- and (Z)-naphthylidene indenes.
Kennesaw State University
15
Potent cyano and carboxamido side-chain analogues of 1', 1'-dimethyl-delta8-tetrahydrocannabinol.
Organix
48
Structural requirements for binding of anandamide-type compounds to the brain cannabinoid receptor.
Hebrew University
8
3-Alkyl-(5,5'-diphenyl)imidazolidineiones as new cannabinoid receptor ligands.
University of Louvain
37
¿-Carbolines: a novel class of cannabinoid agonists with high aqueous solubility and restricted CNS penetration.
AstraZeneca
49
Fatty acid amide hydrolase inhibitors. 3: tetra-substituted azetidine ureas with in vivo activity.
Vernalis (R&D)
28
Resorcinol-sn-glycerol derivatives: novel 2-arachidonoylglycerol mimetics endowed with high affinity and selectivity for cannabinoid type 1 receptor.
University of Siena
20
1-Aryl-5-(1H-pyrrol-1-yl)-1H-pyrazole-3-carboxamide: an effective scaffold for the design of either CB1 or CB2 receptor ligands.
Sapienza University of Rome
3
Characterization of a novel and selective CB1 antagonist as a radioligand for receptor occupancy studies.
Bristol Myers Squibb
3
Asymmetric synthesis and biological evaluation of N-cyclohexyl-4-[1-(2,4-dichlorophenyl)-1-(p-tolyl)methyl]piperazine-1-carboxamide as hCB1 receptor antagonists.
Shanghai Institute of Materia Medica
7
Conformationally constrained analogs of BAY 59-3074 as novel cannabinoid receptor ligands.
Northeastern University
9
Towards rational design of cannabinoid receptor 1 (CB1) antagonists for peripheral selectivity.
Rti International
4
Homology modeling in tandem with 3D-QSAR analyses: a computational approach to depict the agonist binding site of the human CB2 receptor.
University of Genoa
3
Bioactive prenylogous cannabinoid from fiber hemp (Cannabis sativa).
Universita` Del Piemonte Orientale
25
Fluorinated cannabinoid CB2 receptor ligands: synthesis and in vitro binding characteristics of 2-oxoquinoline derivatives.
The University of Texas
17
Investigations on the 4-quinolone-3-carboxylic acid motif. 4. Identification of new potent and selective ligands for the cannabinoid type 2 receptor with diverse substitution patterns and antihyperalgesic effects in mice.
Universita Degli Studi Di Siena
4
Benzyl derivatives with in vitro binding affinity for human opioid and cannabinoid receptors from the fungus Eurotium repens.
The University of Mississippi
1
Synthesis, in vitro and in vivo evaluation of fluorine-18 labelled FE-GW405833 as a PET tracer for type 2 cannabinoid receptor imaging.
Imir K.U. Leuven
34
Tricyclic imidazole antagonists of the Neuropeptide S Receptor.
Merck Research Laboratories
12
Development of endocannabinoid-based chemical probes for the study of cannabinoid receptors.
Universidad Complutense De Madrid
35
Indazole derivatives as novel bradykinin B1 receptor antagonists.
Merck Research Laboratories
53
Decahydroquinoline amides as highly selective CB2 agonists: role of selectivity on in vivo efficacy in a rodent model of analgesia.
Merck Research Laboratories
4
Discovery of indole alkaloids with cannabinoid CB1 receptor antagonistic activity.
Chiba University
43
1,4-Diazepane compounds as potent and selective CB2 agonists: optimization of metabolic stability.
Boehringer Ingelheim Pharmaceuticals
15
Imidazopyridine CB2 agonists: optimization of CB2/CB1 selectivity and implications for in vivo analgesic efficacy.
Merck Research Laboratories
101
Three-dimensional quantitative structure-selectivity relationships analysis guided rational design of a highly selective ligand for the cannabinoid receptor 2.
University of Siena
31
4-Oxo-1,4-dihydropyridines as selective CB2 cannabinoid receptor ligands: structural insights into the design of a novel inverse agonist series.
Universite£? Lille-Nord De France
37
Structure-activity relationships of 2,4-diphenyl-1H-imidazole analogs as CB2 receptor agonists for the treatment of chronic pain.
Merck Research Laboratory
27
Synthesis and biological evaluation of new N-alkyl 1-aryl-5-(1H-pyrrol-1-yl)-1H-pyrazole-3-carboxamides as cannabinoid receptor ligands.
Sapienza University of Rome
20
Synthesis, binding studies and molecular modeling of novel cannabinoid receptor ligands.
German University In Cairo
21
Synthesis and biological evaluation of bivalent ligands for the cannabinoid 1 receptor.
Research Triangle Institute
1
Spiroindolones, a potent compound class for the treatment of malaria.
Swiss Tropical and Public Health Institute
17
Identification and hit-to-lead optimization of a novel class of CB1 antagonists.
Ligand Pharmaceuticals
27
Two distinct classes of novel pyrazolinecarboxamides as potent cannabinoid CB1 receptor agonists.
Abbott Healthcare Products
2
Discovery of cannabinoid-1 receptor antagonists by virtual screening.
Korea Research Institute of Chemical Technology
9
Synthesis and cannabinoid-1 receptor binding affinity of conformationally constrained analogs of taranabant.
Merck Research Laboratories
11
Rational design of a novel peripherally-restricted, orally active CB(1) cannabinoid antagonist containing a 2,3-diarylpyrrole motif.
Sanofi-Aventis R&D
34
Dihydro-pyrano[2,3-b]pyridines and tetrahydro-1,8-naphthyridines as CB1 receptor inverse agonists: synthesis, SAR and biological evaluation.
Merck Research Laboratories
29
Discovery of N-[(4R)-6-(4-chlorophenyl)-7-(2,4-dichlorophenyl)-2,2-dimethyl-3,4-dihydro-2H-pyrano[2,3-b]pyridin-4-yl]-5-methyl-1H-pyrazole-3-carboxamide (MK-5596) as a novel cannabinoid-1 receptor (CB1R) inverse agonist for the treatment of obesity.
Merck Research Laboratories
20
Furo[2,3-b]pyridine-based cannabinoid-1 receptor inverse agonists: synthesis and biological evaluation. Part 1.
Merck Research Laboratories
5
Radiosynthesis of novel carbon-11-labeled triaryl ligands for cannabinoid-type 2 receptor.
National Institute of Radiological Sciences
30
Discovery of benzhydrylpiperazine derivatives as CB1 receptor inverse agonists via privileged structure-based approach.
Chinese Academy of Sciences
2
Synthesis and in vitro autoradiographic evaluation of a novel high-affinity radioiodinated ligand for imaging brain cannabinoid subtype-1 receptors.
National Institute of Mental Health
102
Synthesis and structure-activity relationship of 1,2,4-triazole-containing diarylpyrazolyl carboxamide as CB1 cannabinoid receptor-ligand.
Green Cross
7
Synthesis and biological evaluation of new potential inhibitors of N-acylethanolamine hydrolyzing acid amidase.
University of Salerno
10
Synthesis and in vitro biological evaluation of carbon-11-labeled quinoline derivatives as new candidate PET radioligands for cannabinoid CB2 receptor imaging.
Indiana University School of Medicine
30
Synthesis and structure-activity relationship of substitutions at the C-1 position of Delta9-tetrahydrocannabinol.
AMRI
33
Conversion of 4-cyanomethyl-pyrazole-3-carboxamides into CB1 antagonists with lowered propensity to pass the blood-brain-barrier.
7Tm Pharma
32
Non-aromatic A-ring replacement in the triaryl bis-sulfone CB2 receptor inhibitors.
Merck Research Laboratories
54
Exploring SAR features in diverse library of 4-cyanomethyl-pyrazole-3-carboxamides suitable for further elaborations as CB1 antagonists.
7Tm Pharma
23
Novel sulfamoyl benzamides as selective CB(2) agonists with improved in vitro metabolic stability.
Adolor
15
Design, synthesis, biological properties, and molecular modeling investigations of novel tacrine derivatives with a combination of acetylcholinesterase inhibition and cannabinoid CB1 receptor antagonism.
Solvay Pharma
69
Indol-3-ylcycloalkyl ketones: effects of N1 substituted indole side chain variations on CB(2) cannabinoid receptor activity.
Abbott Laboratories
20
Discovery of 1-[4-(3-chlorophenylamino)-1-methyl-1H-pyrrolo[3,2-c]pyridin-7-yl]-1-morpholin-4-ylmethanone (GSK554418A), a brain penetrant 5-azaindole CB2 agonist for the treatment of chronic pain.
Glaxosmithkline
15
Novel pyridine derivatives as potent and selective CB2 cannabinoid receptor agonists.
Adolor
19
Bioisosteric replacement of the hydrazide pharmacophore of the cannabinoid-1 receptor antagonist SR141716A. Part I: potent, orally-active 1,4-disubstituted imidazoles.
Pfizer
19
Discovery of N-(3-(morpholinomethyl)-phenyl)-amides as potent and selective CB2 agonists.
Adolor
20
Synthesis and evaluation of N-[(1S,2S)-3-(4-chlorophenyl)-2-(3-cyanophenyl)-1-methylpropyl]-2-methyl-2-aminopropanamide as human cannabinoid-1 receptor (CB1R) inverse agonists.
Merck Research Laboratories
6
Synthesis and SAR of 1,4,5,6-tetrahydropyridazines as potent cannabinoid CB1 receptor antagonists.
Solvay Pharma
23
Rapid assessment of a novel series of selective CB(2) agonists using parallel synthesis protocols: A Lipophilic Efficiency (LipE) analysis.
Pfizer
7
Fatty acid amide hydrolase inhibitors. Surprising selectivity of chiral azetidine ureas.
Vernalis (R&D)
2
Total synthesis of photoactivatable or fluorescent anandamide probes: novel bioactive compounds with angiogenic activity.
University of Montpellier
16
Structure activity relationships of tetrahydrocannabinol analogues on human cannabinoid receptors
TBA
26
Discovery of 2-[5-(4-chloro-phenyl)-1-(2,4-dichloro-phenyl)-4-ethyl-1H-pyrazol-3-yl]-1,5,5-trimethyl-1,5-dihydro-imidazol-4-thione (BPR-890) via an active metabolite. A novel, potent and selective cannabinoid-1 receptor inverse agonist with high antiobesity efficacy in DIO mice.
National Health Research Institutes
25
New resorcinol-anandamide"hybrids" as potent cannabinoid receptor ligands endowed with antinociceptive activity in vivo.
Universita Degli Studi Di Siena
35
Pyridopyrimidine based cannabinoid-1 receptor inverse agonists: Synthesis and biological evaluation.
Merck Research Laboratories
11
Hair growth stimulator property of thienyl substituted pyrazole carboxamide derivatives as a CB1 receptor antagonist with in vivo antiobesity effect.
Zydus Research Centre
66
1-Sulfonyl-4-acylpiperazines as selective cannabinoid-1 receptor (CB1R) inverse agonists for the treatment of obesity.
Merck Research Laboratories
23
Quantitative structure-activity relationship (QSAR) for a series of novel cannabinoid derivatives using descriptors derived from semi-empirical quantum-chemical calculations.
St. Jude Children'S Research Hospital
6
Design and synthesis of novel tri-aryl CB2 selective cannabinoid ligands.
University of Tennessee-Memphis
17
1,2,3-Triazole derivatives as new cannabinoid CB1 receptor antagonists.
National Central University
25
Discovery of alpha-amidosulfones as potent and selective agonists of CB2: synthesis, SAR, and pharmacokinetic properties.
Amgen
7
New analgesics synthetically derived from the paracetamol metabolite N-(4-hydroxyphenyl)-(5Z,8Z,11Z,14Z)-icosatetra-5,8,11,14-enamide.
Martin-Luther-Universitaet
20
2-Arylimino-5,6-dihydro-4H-1,3-thiazines as a new class of cannabinoid receptor agonists. Part 3: Synthesis and activity of isosteric analogs.
Shionogi
22
Tetrahydrolipstatin analogues as modulators of endocannabinoid 2-arachidonoylglycerol metabolism.
Sapienza University of Rome
5
Discovery and labeling of high-affinity 3,4-diarylpyrazolines as candidate radioligands for in vivo imaging of cannabinoid subtype-1 (CB1) receptors.
National Institute of Mental Health
41
Bioisosteric replacement of the pyrazole 5-aryl moiety of N-(piperidin-1-yl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide (SR141716A). A novel series of alkynylthiophenes as potent and selective cannabinoid-1 receptor antagonists.
National Health Research Institutes
26
Structural modifications of N-arylamide oxadiazoles: Identification of N-arylpiperidine oxadiazoles as potent and selective agonists of CB2.
Amgen
1
Comparative molecular dynamics simulations of the potent synthetic classical cannabinoid ligand AMG3 in solution and at binding site of the CB1 and CB2 receptors.
The National Hellenic Research Foundation
18
Exploring the substituent effects on a novel series of C1'-dimethyl-aryl Delta8-tetrahydrocannabinol analogs.
University of Tennessee-Memphis
9
Conformationally constrained analogues of N-(piperidinyl)-5-(4-chlorophenyl)-1-(2,4- dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide (SR141716): design, synthesis, computational analysis, and biological evaluations.
Research Triangle Institute
15
Analogs of JHU75528, a PET ligand for imaging of cerebral cannabinoid receptors (CB1): development of ligands with optimized lipophilicity and binding affinity.
Johns Hopkins University School of Medicine
9
Rational design, synthesis and biological evaluation of new 1,5-diarylpyrazole derivatives as CB1 receptor antagonists, structurally related to rimonabant.
Università
32
Design, synthesis and biological evaluation of piperazine analogues as CB1 cannabinoid receptor ligands.
Central Research Institute
18
Synthesis and cannabinoid activity of 1-substituted-indole-3-oxadiazole derivatives: novel agonists for the CB1 receptor.
Monash University (Parkville Campus)
7
Synthesis and Pharmacological Characterization of Novel Peripheral Cannabinoid-1 Receptor Blockers Based on a Tricyclic Scaffold.
The Hebrew University of Jerusalem
1
Antimalarial (+)-trans-hexahydrodibenzopyran derivatives from Machaerium multiflorum.
University of Mississippi
4
Chiral recognition of CIAC001 isomers in regulating pyruvate kinase M2 and mitigating neuroinflammation.
Hunan Institute of Science and Technology
7
Chemistry and pharmacological aspects of furanoid cannabinoids and related compounds: Is furanoid cannabinoids open a new dimension towards the non-psychoactive cannabinoids?
CSIR-Indian Institute of Integrative Medicine
29
Stereoisomers of cannabidiols and their pharmacological activities - A potentially novel direction for cannabinoids.
University Health Network
11
Structure-Based Discovery of a Series of Covalent, Orally Bioavailable, and Selective BFL1 Inhibitors.
AstraZeneca
44
Arylsulfonamide CB2 receptor agonists: SAR and optimization of CB2 selectivity.
Evotec (Uk)
1
Exploring the 1,3-benzoxazine chemotype for cannabinoid receptor 2 as a promising anti-cancer therapeutic.
University of the Studies of Bari "Aldo Moro"
48
Discovery and SAR of JTE-151: A Novel RORγ Inhibitor for Clinical Development.
Japan Tobacco
2
Diaryl dihydropyrazole-3-carboxamides with significant in vivo antiobesity activity related to CB1 receptor antagonism: synthesis, biological evaluation, and molecular modeling in the homology model.
Zydus Research Centre
31
New 1,2,3,4-tetrahydropyrrolo[3,4-b]indole derivatives as selective CB2 receptor agonists.
AstraZeneca
40
Novel pyrrole based CB2 agonists: New insights on CB2 receptor role in regulating neurotransmitters' tone.
University of Salerno
23
Triazoles in Medicinal Chemistry: Physicochemical Properties, Bioisosterism, and Application.
China Pharmaceutical University
69
Potent, Selective Agonists for the Cannabinoid-like Orphan G Protein-Coupled Receptor GPR18: A Promising Drug Target for Cancer and Immunity.
University of Bonn
7
Sulfonamide derivatives as new potent and selective CB2 cannabinoid receptor agonists.
Taisho Pharmaceutical
12
Discovery of N-{(1S,2S)-2-(3-cyanophenyl)- 3-[4-(2-[18F]fluoroethoxy)phenyl]-1-methylpropyl}- 2-methyl-2-[(5-methylpyridin-2-yl)oxy]propanamide, a cannabinoid-1 receptor positron emission tomography tracer suitable for clinical use.
TBA
10
Metabolically labile cannabinoid esters: a 'soft drug' approach for the development of cannabinoid-based therapeutic drugs.
Università
28
2-Arylimino-5,6-dihydro-4H-1,3-thiazines as a new class of cannabinoid receptor agonists. Part 2: orally bioavailable compounds.
Shionogi
35
2-Arylimino-5,6-dihydro-4H-1,3-thiazines as a new class of cannabinoid receptor agonists. Part 1: discovery of CB2 receptor selective compounds.
Shionogi
49
The application of 3D-QSAR studies for novel cannabinoid ligands substituted at the C1' position of the alkyl side chain on the structural requirements for binding to cannabinoid receptors CB1 and CB2.
The National Hellenic Research Foundation
29
Discovery of pyrazine carboxamide CB1 antagonists: the introduction of a hydroxyl group improves the pharmaceutical properties and in vivo efficacy of the series.
Pharmaceutical Research Institute
39
Optimization of triaryl bis-sulfones as cannabinoid-2 receptor ligands.
Schering-Plough Research Institute
2
Synthesis and Evaluation of Natural and Unnatural Tetrahydrocannabiorcol for Its Potential Use in Neuropathologies.
Csir-Indian Institute of Integrative Medicine
41
Optimization of imidazole amide derivatives as cannabinoid-1 receptor antagonists for the treatment of obesity.
Bayer Healthcare
23
Development of potent and selective FAAH inhibitors with improved drug-like properties as potential tools to treat neuroinflammatory conditions.
Universit£
34
Substituted acyclic sulfonamides as human cannabinoid-1 receptor inverse agonists.
Merck Research Laboratories
37
Lead optimization of 5,6-diarylpyridines as CB1 receptor inverse agonists.
Merck Research Laboratories
20
N-adamantyl-anthranil amide derivatives: New selective ligands for the cannabinoid receptor subtype 2 (CB2R).
University of The Studies of Bari "Aldo Moro
1
Synthesis and biological evaluation of several structural analogs of 2-arachidonoylglycerol, an endogenous cannabinoid receptor ligand.
Teikyo University
5
Recent advances in chemistry and bioactivity of marine cyanobacteria Moorea species.
Ningbo University
34
Constrained analogs of CB-1 antagonists: 1,5,6,7-Tetrahydro-4H-pyrrolo[3,2-c]pyridine-4-one derivatives.
Bayer Healthcare
6
Biarylpyrazole inverse agonists at the cannabinoid CB1 receptor: importance of the C-3 carboxamide oxygen/lysine3.28(192) interaction.
University of North Carolina At Greensboro
11
Cannabinoid Receptor Subtype 2 (CB2R) in a Multitarget Approach: Perspective of an Innovative Strategy in Cancer and Neurodegeneration.
Cnr-Institute of Crystallography
25
Thienopyrimidine Derivatives as GPR55 Receptor Antagonists: Insight into Structure-Activity Relationship.
IQM-CSIC
6
Covalent cannabinoid receptor ligands - structural insight and selectivity challenges.
University of Otago Dunedin
28
Recent Scaffold Hopping Applications in Central Nervous System Drug Discovery.
The University of Sydney
14
Reversible Monoacylglycerol Lipase Inhibitors: Discovery of a New Class of Benzylpiperidine Derivatives.
University of Pisa
11
Oxyhomologues of anandamide and related endolipids: chemoselective synthesis and biological activity.
University of Piemonte Orientale
33
Improved cyclobutyl nabilone analogs as potent CB1 receptor agonists.
National and Kapodistrian University of Athens
17
Pyrazole-containing pharmaceuticals: target, pharmacological activity, and their SAR studies.
Tianjin University
59
The Repertoire of Small-Molecule PET Probes for Neuroinflammation Imaging: Challenges and Opportunities beyond TSPO.
Massachusetts General Hospital
8
Design, Synthesis, and Biological Activity of New CB2 Receptor Ligands: from Orthosteric and Allosteric Modulators to Dualsteric/Bitopic Ligands.
University of Pisa
30
Structure-Based Design, Optimization, and Development of [
Helmholtz-Zentrum Dresden-Rossendorf (Hzdr)
2
Synthesis and in vivo validation of [O-methyl-11C]2-{4-[4-(7-methoxynaphthalen-1-yl)piperazin- 1-yl]butyl}-4-methyl-2H-[1,2,4]triazine-3,5-dione: a novel 5-HT1A receptor agonist positron emission tomography ligand.
Columbia University College of Physicians and Surgeons
18
Synthesis of functionalized 1,8-naphthyridinones and their evaluation as novel, orally active CB1 receptor inverse agonists.
Merck Research Laboratories
61
Structure-Activity Relationship in the Leucettine Family of Kinase Inhibitors.
Manros Therapeutics & Perha Pharmaceuticals
19
Substituted 5,5'-diphenyl-2-thioxoimidazolidin-4-one as CB1 cannabinoid receptor ligands: synthesis and pharmacological evaluation.
Université
3
Synthesis and antitumour evaluation of indole-2-carboxamides against paediatric brain cancer cells.
Curtin University
36
Synthesis and activity of 4,5-diarylimidazoles as human CB1 receptor inverse agonists.
Merck Research Laboratories
22
Triaryl bis-sulfones as a new class of cannabinoid CB2 receptor inhibitors: identification of a lead and initial SAR studies.
Schering-Plough Research Institute
54
Synthesis and SAR of 5,6-diarylpyridines as human CB1 inverse agonists.
Merck Research Laboratories
29
Carbon-silicon switch led to the discovery of novel synthetic cannabinoids with therapeutic effects in a mouse model of multiple sclerosis.
Shanghaitech University
19
Design, synthesis, and pharmacological profiling of cannabinoid 1 receptor allosteric modulators: Preclinical efficacy of C2-group GAT211 congeners for reducing intraocular pressure.
Northeastern University
23
Rational Remodeling of Atypical Scaffolds for the Design of Photoswitchable Cannabinoid Receptor Tools.
Shanghaitech University
36
Synthesis, Biological Evaluation, and Molecular Modeling Studies of 3,4-Diarylpyrazoline Series of Compounds as Potent, Nonbrain Penetrant Antagonists of Cannabinoid-1 (CB
National Institute On Alcohol Abuse and Alcoholism
38
Development of 3-(4-Chlorophenyl)-1-(phenethyl)urea Analogues as Allosteric Modulators of the Cannabinoid Type-1 Receptor: RTICBM-189 is Brain Penetrant and Attenuates Reinstatement of Cocaine-Seeking Behavior.
Research Triangle Institute
15
Novel Functionalized Cannabinoid Receptor Probes: Development of Exceptionally Potent Agonists.
The Scripps Research Institute
55
Synthesis and SAR evaluation of coumarin derivatives as potent cannabinoid receptor agonists.
Karlsruhe Institute of Technology (Kit)
26
Rational design of cannabinoid type-1 receptor allosteric modulators: Org27569 and PSNCBAM-1 hybrids.
Research Triangle Institute
26
Potent imidazole and triazole CB1 receptor antagonists related to SR141716.
Neurocrine Biosciences
30
Synthesis, biological properties, and molecular modeling investigations of novel 3,4-diarylpyrazolines as potent and selective CB(1) cannabinoid receptor antagonists.
Solvay Pharma
14
Cannabinoid Receptor Agonists for the Potential Treatment of Pain, Neurological Disorders, Fibrotic Diseases, Obesity, and Many More.
Therachem Research Medilab
7
Synthesis, Molecular Pharmacology, and Structure-Activity Relationships of 3-(Indanoyl)indoles as Selective Cannabinoid Type 2 Receptor Antagonists.
West Virginia University
3
An aromatic microdomain at the cannabinoid CB(1) receptor constitutes an agonist/inverse agonist binding region.
Forbes Norris Als/Mda Research Center
7
Synthesis and testing of novel phenyl substituted side-chain analogues of classical cannabinoids.
University of Tennessee-Memphis
53
From a Designer Drug to the Discovery of Selective Cannabinoid Type 2 Receptor Agonists with Favorable Pharmacokinetic Profiles for the Treatment of Systemic Sclerosis.
East China Normal University
8
The discovery of a potent and selective pyrazolo-[2,3-e]-[1,2,4]-triazine cannabinoid type 2 receptor agonist.
The University of Sydney
27
Design, synthesis and biological evaluation of second-generation benzoylpiperidine derivatives as reversible monoacylglycerol lipase (MAGL) inhibitors.
University of Pisa
38
Amide Bond Bioisosteres: Strategies, Synthesis, and Successes.
University of Nebraska Medical Center
2
Impact of Allosteric Modulation in Drug Discovery: Innovation in Emerging Chemical Modalities.
Therapeutics
24
New cannabinoid receptor antagonists as pharmacological tool.
Instituto De Qu£Mica M£Dica (Csic)
23
Synthesis and biological evaluation of a ring analogs of the selective CB2 inverse agonist SMM-189.
University of Tennessee Health Science Center
6
Treatment of Metabolic Disorders with CB-1 Receptor Inverse Agonists.
Therachem Research Medilab (India)
4
Synthesis and biological evaluation of indole-2-carboxamides bearing photoactivatable functionalities as novel allosteric modulators for the cannabinoid CB1 receptor.
Texas A&M University
15
The endocannabinoid system dual-target ligand N-cycloheptyl-1,2-dihydro-5-bromo-1-(4-fluorobenzyl)-6-methyl-2-oxo-pyridine-3-carboxamide improves disease severity in a mouse model of multiple sclerosis.
University of Pisa
8
Conformational memories and the endocannabinoid binding site at the cannabinoid CB1 receptor.
Kennesaw State University
4
7-Azaindolequinuclidinones (7-AIQD): A novel class of cannabinoid 1 (CB1) and cannabinoid 2 (CB2) receptor ligands.
University of Arkansas For Medical Sciences
41
Discovery and Characterization of BAY 1214784, an Orally Available Spiroindoline Derivative Acting as a Potent and Selective Antagonist of the Human Gonadotropin-Releasing Hormone Receptor as Proven in a First-In-Human Study in Postmenopausal Women.
Bayer
8
Discovery of PEGylated 6-Benzhydryl-4-amino-quinazolines as Peripherally Restricted CB
Janssen Research & Development
41
Focused structure-activity relationship profiling around the 2-phenylindole scaffold of a cannabinoid type-1 receptor agonist-positive allosteric modulator: site-III aromatic-ring congeners with enhanced activity and solubility.
Northeastern University
5
Synthesis of the Major Mammalian Metabolites of THCV.
National Research Council of Italy
30
Leveraging an Open Science Drug Discovery Model to Develop CNS-Penetrant ALK2 Inhibitors for the Treatment of Diffuse Intrinsic Pontine Glioma.
Ontario Institute For Cancer Research
24
The discovery of azetidine-piperazine di-amides as potent, selective and reversible monoacylglycerol lipase (MAGL) inhibitors.
Janssen Research & Development
28
Synthetic bioactive olivetol-related amides: The influence of the phenolic group in cannabinoid receptor activity.
University of Siena
36
Exploration of Alternative Scaffolds for P2Y
National Institute of Diabetes and Digestive and Kidney Diseases
21
Design, Synthesis, and Physicochemical and Pharmacological Profiling of 7-Hydroxy-5-oxopyrazolo[4,3-
University of Siena
32
Discovery of Aryl Formyl Piperidine Derivatives as Potent, Reversible, and Selective Monoacylglycerol Lipase Inhibitors.
China Pharmaceutical University
61
Development of indole sulfonamides as cannabinoid receptor negative allosteric modulators.
University of Aberdeen
54
Peripherally Selective Cannabinoid 1 Receptor (CB1R) Agonists for the Treatment of Neuropathic Pain.
Research Triangle Institute
16
Synthesis, molecular modeling and SAR study of novel pyrazolo[5,1-f][1,6]naphthyridines as CB
University of Sassari
11
Inhibitors of diacylglycerol lipases in neurodegenerative and metabolic disorders.
Leiden University
47
Chromenopyrazole, a Versatile Cannabinoid Scaffold with in Vivo Activity in a Model of Multiple Sclerosis.
IQM-CSIC
34
Optimization of a Benzoylpiperidine Class Identifies a Highly Potent and Selective Reversible Monoacylglycerol Lipase (MAGL) Inhibitor.
University of Pisa
36
Synthesis and Pharmacological Evaluation of 1-Phenyl-3-Thiophenylurea Derivatives as Cannabinoid Type-1 Receptor Allosteric Modulators.
Research Triangle Institute
35
QSAR analysis of Delta(8)-THC analogues: relationship of side-chain conformation to cannabinoid receptor affinity and pharmacological potency.
Research Triangle Institute
33
Functionalized 6-(piperidin-1-yl)-8,9-diphenyl purines as inverse agonists of the CB1 receptor - SAR efforts towards selectivity and peripheralization.
Rti International
23
1-(2-Hydroxybenzoyl)-thiosemicarbazides are promising antimicrobial agents targeting d-alanine-d-alanine ligase in bacterio.
University of Louvain
30
Application of Fluorine- and Nitrogen-Walk Approaches: Defining the Structural and Functional Diversity of 2-Phenylindole Class of Cannabinoid 1 Receptor Positive Allosteric Modulators.
Northeastern University
86
Biased Ligands of G Protein-Coupled Receptors (GPCRs): Structure-Functional Selectivity Relationships (SFSRs) and Therapeutic Potential.
Shanghaitech University
17
Divalent cannabinoid-1 receptor ligands: A linker attachment point survey of SR141716A for development of high-affinity CB1R molecular probes.
University of Auckland
8
Identification of CB1 Receptor Allosteric Sites Using Force-Biased MMC Simulated Annealing and Validation by Structure-Activity Relationship Studies.
University of North Carolina At Greensboro
33
Structure-activity relationships of thiazole and benzothiazole derivatives as selective cannabinoid CB2 agonists with in vivo anti-inflammatory properties.
German University In Cairo
20
Discovery of novel benzofuran-based compounds with neuroprotective and immunomodulatory properties for Alzheimer's disease treatment.
University of Bologna
31
Functionalized 6-(Piperidin-1-yl)-8,9-Diphenyl Purines as Peripherally Restricted Inverse Agonists of the CB1 Receptor.
Rti International
18
Dual-Acting Cholinesterase-Human Cannabinoid Receptor 2 Ligands Show Pronounced Neuroprotection in Vitro and Overadditive and Disease-Modifying Neuroprotective Effects in Vivo.
Julius Maximilian University of W£Rzburg
12
The Trifluoromethyl Group as a Bioisosteric Replacement of the Aliphatic Nitro Group in CB
University of Aberdeen
3
Preventing Morphine-Seeking Behavior through the Re-Engineering of Vincamine's Biological Activity.
University of Florida
5
Isolation of a High-Affinity Cannabinoid for the Human CB1 Receptor from a Medicinal
University of Modena and Reggio Emilia
13
Polycyclic Maleimide-based Scaffold as New Privileged Structure for Navigating the Cannabinoid System Opportunities.
University of Bologna
4
Importance of the C-1 substituent in classical cannabinoids to CB2 receptor selectivity: synthesis and characterization of a series of O,2-propano-delta 8-tetrahydrocannabinol analogs.
Kennesaw State University
27
Synthesis of novel 2-(1-adamantanylcarboxamido)thiophene derivatives. Selective cannabinoid type 2 (CB2) receptor agonists as potential agents for the treatment of skin inflammatory disease.
University of Siena
5
Synthesis and pharmacology of a very potent cannabinoid lacking a phenolic hydroxyl with high affinity for the CB2 receptor.
Clemson University
10
Novel Electrophilic and Photoaffinity Covalent Probes for Mapping the Cannabinoid 1 Receptor Allosteric Site(s).
Dalhousie University
3
Benzimidazole: an emerging scaffold for analgesic and anti-inflammatory agents.
Asbasjsm College of Pharmacy
15
Design, synthesis, biological evaluation, and comparative docking study of 1,2,4-triazolones as CB1 receptor selective antagonists.
Zhejiang University
2
Functionally Optimized Neuritogenic Farinosone C Analogs: SAR-Study and Investigations on Their Mode of Action.
University of Basel
28
1,2-Dihydro-2-oxopyridine-3-carboxamides: the C-5 substituent is responsible for functionality switch at CB2 cannabinoid receptor.
University of Pisa
2
Synthesis and preliminary evaluation of a new fluorine-18 labelled triazine derivative for PET imaging of cannabinoid CB2 receptor.
Sanofi R&D
26
Development of fluorinated CB(2) receptor agonists for PET studies.
Institut F£R Pharmazeutische Und Medizinische Chemie Der Universit£T M£Nster
27
Selective cannabinoid receptor type 2 (CB2) agonists: optimization of a series of purines leading to the identification of a clinical candidate for the treatment of osteoarthritic pain.
Lilly Research Laboratories
8
Identification of CB1/CB2 ligands from Zanthoxylum bungeanum.
National Institute On Aging
4
Synthetic cannabinoid quinones: preparation, in vitro antiproliferative effects and in vivo prostate antitumor activity.
Instituto De Qu£Mica M£Dica
45
Mastering tricyclic ring systems for desirable functional cannabinoid activity.
The University of Montana
10
Peripherally selective diphenyl purine antagonist of the CB1 receptor.
Research Triangle Institute
1
An effective prodrug strategy to selectively enhance ocular exposure of a cannabinoid receptor (CB1/2) agonist.
Novartis Institutes For Biomedical Research
17
Selective CB2 agonists with anti-pruritic activity: discovery of potent and orally available bicyclic 2-pyridones.
Shionogi
41
Discovery of 7-oxopyrazolo[1,5-a]pyrimidine-6-carboxamides as potent and selective CB(2) cannabinoid receptor inverse agonists.
University of Ferrara
22
Pharmaceutical and medicinal significance of sulfur (S
Wuhan University of Technology
30
Combined 3D QSAR and molecular docking studies to reveal novel cannabinoid ligands with optimum binding activity.
The National Hellenic Research Foundation
20
A 3D-QSAR study on the structural requirements for binding to CB(1) and CB(2) cannabinoid receptors.
University of Catania
41
Discovery of long-chain salicylketoxime derivatives as monoacylglycerol lipase (MAGL) inhibitors.
University of Pisa
61
6-Benzhydryl-4-amino-quinolin-2-ones as Potent Cannabinoid Type 1 (CB
Janssen Research & Development
15
Discovery and Lead Optimization of Atropisomer D1 Agonists with Reduced Desensitization.
Pfizer
34
Alkyl indole-based cannabinoid type 2 receptor tools: Exploration of linker and fluorophore attachment.
University of Otago
11
Bioactive products from singlet oxygen photooxygenation of cannabinoids.
The University of Mississippi
3
2,4-Diamino-6-methylpyrimidines for the potential treatment of Chagas' disease.
University of Dundee
37
Synthesis and pharmacological characterization of functionalized 6-piperazin-1-yl-purines as cannabinoid receptor 1 (CB1) inverse agonists.
Rti International
32
Blocking Alcoholic Steatosis in Mice with a Peripherally Restricted Purine Antagonist of the Type 1 Cannabinoid Receptor.
Rti International
20
Novel sulfenamides and sulfonamides based on pyridazinone and pyridazine scaffolds as CB
University of Sassari
1
Polyphenolic Phytochemicals in Cancer Prevention and Therapy: Bioavailability versus Bioefficacy.
University of Valencia
5
Novel analogs of PSNCBAM-1 as allosteric modulators of cannabinoid CB1 receptor.
University of Pisa
78
Therapeutic Potential of Fatty Acid Amide Hydrolase, Monoacylglycerol Lipase, and N-Acylethanolamine Acid Amidase Inhibitors.
University of Lille
9
Synthesis of oxidative metabolites of CRA13 and their analogs: Identification of CRA13 active metabolites and analogs thereof with selective CB
Kyung Hee University
34
Structure-activity relationships of imidazothiazinones and analogs as antagonists of the cannabinoid-activated orphan G protein-coupled receptor GPR18.
University of Bonn
16
Polypharmacological profile of 1,2-dihydro-2-oxo-pyridine-3-carboxamides in the endocannabinoid system.
University of Bern
17
Discovery of APD371: Identification of a Highly Potent and Selective CB
Arena Pharmaceuticals
2
Iodine-Promoted Aromatization of p-Menthane-Type Phytocannabinoids.
University of Eastern Piedmont
35
Developing pyridazine-3-carboxamides to be CB2 agonists: The design, synthesis, structure-activity relationships and docking studies.
Zhejiang University
24
Design, synthesis and biological evaluation of GPR55 agonists.
University of North Carolina At Greensboro
6
Biological evaluation of pyridone alkaloids on the endocannabinoid system.
University of Bern
32
Novel Diarylurea Based Allosteric Modulators of the Cannabinoid CB1 Receptor: Evaluation of Importance of 6-Pyrrolidinylpyridinyl Substitution.
Research Triangle Institute
40
Amidoalkylindoles as Potent and Selective Cannabinoid Type 2 Receptor Agonists with in Vivo Efficacy in a Mouse Model of Multiple Sclerosis.
East China Normal University
13
Discovery of Trifluoromethyl Glycol Carbamates as Potent and Selective Covalent Monoacylglycerol Lipase (MAGL) Inhibitors for Treatment of Neuroinflammation.
Pfizer
28
Discovery of 1,5-Diphenylpyrazole-3-Carboxamide Derivatives as Potent, Reversible, and Selective Monoacylglycerol Lipase (MAGL) Inhibitors.
University of Ferrara
13
Perspectives of Cannabinoid Type 2 Receptor (CB2R) Ligands in Neurodegenerative Disorders: Structure-Affinity Relationship (SAfiR) and Structure-Activity Relationship (SAR) Studies.
University of Bari Aldo Moro
21
Structure-Activity Relationships and Computational Investigations into the Development of Potent and Balanced Dual-Acting Butyrylcholinesterase Inhibitors and Human Cannabinoid Receptor 2 Ligands with Pro-Cognitive in Vivo Profiles.
Julius Maximilian University of W£Rzburg
43
Identification of N-{cis-3-[Methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]cyclobutyl}propane-1-sulfonamide (PF-04965842): A Selective JAK1 Clinical Candidate for the Treatment of Autoimmune Diseases.
Pfizer
23
Structure-Affinity Relationships and Structure-Kinetic Relationships of 1,2-Diarylimidazol-4-carboxamide Derivatives as Human Cannabinoid 1 Receptor Antagonists.
Leiden University
46
PIPERIDINYL INDOLE DERIVATIVES, PREPARATION METHODS AND MEDICINAL USES THEREOF
Hansoh Bio
128
SPIROCYCLIC MODULATORS OF CHOLESTEROL BIOSYNTHESIS AND THEIR USE FOR PROMOTING REMYELINATION
Genentech
20
(Cyano-dimethyl-methyl)-isoxazoles and -[1,3,4]thiadiazoles
Centrexion Therapeutics
21
Fused bicyclic (hetero)aromatic compounds useful for the treatment of cancers
Jazz Pharmaceuticals Ireland
18
Carboxylic acid URAT1 inhibitor containing diarylmethane structure, preparation method and use thereof
Tianjin Institute of Pharmaceutical Research
18
Tetrahydroquinoline substituted hydroxamic acids as selective histone deacetylase 6 inhibitors
University of Illinois
330
Benzenesulfonamide compounds and their use as therapeutic agents
Xenon Pharmaceuticals
16
JAK kinase inhibitor compounds for treatment of respiratory disease
Theravance Biopharma R&D Ip
78
Aryl and heteroaryl-fused tetrahydro-1,4-oxazepine amides as somatostatin receptor subtype 4 (SSTR4) agonists
Boehringer Ingelheim International
4
Susceptibility of cord blood antioxidant enzymes glutathione reductase, glutathione peroxidase and glutathione S-transferase to different antibiotics: in vitro approach.
Ondokuz Mayis University
24
Design, synthesis and biological evaluation of CB1 cannabinoid receptor ligands derived from the 1,5-diarylpyrazole scaffold.
Nanchang University School of Pharmaceutical Science
28
Identification of the first in silico-designed TREK1 antagonists that block channel currents dose dependently.
Korea Institute of Science and Technology
8
Synthesis of 2-acylated and sulfonated 4-hydroxycoumarins: In vitro urease inhibition and molecular docking studies.
Comsats Institute of Information Technology
51
7-(heteroaryl-amino)-6,7,8,9-tetrahydropyrido[1,2-a]indol acetic acid derivatives and their use as prostaglandin D2 receptor modulators
Actelion Pharmaceuticals
21
Hydroxybenzaldoximes Are D-GAP-Competitive Inhibitors of E. coli 1-Deoxy-D-Xylulose-5-Phosphate Synthase.
The Johns Hopkins University School of Medicine
189
Pyrazolopyrrolidine derivatives and their use in the treatment of disease
Novartis
94
Diamide compounds having muscarinic receptor antagonist and β2 adrenergic receptor agonist activity
Theravance Respiratory
16
Sulfone-substituted anilinopyrimidine derivatives as CDK inhibitors, the production thereof, and use as a medicine
Bayer Intellectual Property
12
Design, synthesis, molecular docking studies and in vitro screening of ethyl 4-(3-benzoylthioureido) benzoates as urease inhibitors.
Quaid-I-Azam University, Islamabad, Pakistan.
19
Chemical interrogation of FOXO3a nuclear translocation identifies potent and selective inhibitors of phosphoinositide 3-kinases.
Spanish National Cancer Research Center (Cnio)
6
Live cell monitoring of mu-opioid receptor-mediated G-protein activation reveals strong biological activity of close morphine biosynthetic precursors.
University of WÜRzburg
5
Biochemistry and pharmacology of epitope-tagged alpha(1)-adrenergic receptor subtypes.
Emory University
2
The pharmacological characterization of a novel selective 5-hydroxytryptamine1A receptor antagonist, NAD-299.
Preclinical R & D, Astra Arcus
17
Design, synthesis, and SAR of cis-1,2-diaminocyclohexane derivatives as potent factor Xa inhibitors. Part I: exploration of 5-6 fused rings as alternative S1 moieties.
Daiichi Sankyo
10
Glycogen phosphorylase inhibitory effects of 2-oxo-1,2-dihydropyridin-3-yl amide derivatives.
Griffith University
28
Pyrazole-based cathepsin S inhibitors with arylalkynes as P1 binding elements.
Johnson & Johnson Pharmaceutical
56
Development of potent purine-derived nitrile inhibitors of the trypanosomal protease TbcatB.
University of California San Francisco
34
Carbonic anhydrase inhibitors. The mitochondrial isozyme VB as a new target for sulfonamide and sulfamate inhibitors.
Kochi Medical School
26
6-aryl-pyrazolo[3,4-b]pyridines: potent inhibitors of glycogen synthase kinase-3 (GSK-3).
Glaxosmithkline